AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00916656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate, Human (FCH)
Description: Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually.
Study NCT00916656 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cryoprecipitate
Description: Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
Study NCT03639506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection (ICSI)
Description: intracytoplasmic sperm injection (ICSI)
Study NCT04545047 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 convalescent plasma
Description: Convalescent plasma collected from individuals who have recovered from COVID-19
Study NCT02644941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study NCT02644941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePTFE graft
Description: Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study NCT03559959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
Study NCT01000649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 1.25
Description: FE 202158 at dose 1.25 ng/kg/min infused.
Study NCT01000649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 2.5
Description: FE 202158 at dose 2.5 ng/kg/min infused.
Study NCT01000649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 3.75
Description: FE 202158 at dose 3.75 ng/kg/min infused.
Study NCT01000649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline infused.
Study NCT01394835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha -1 Antitrypsin
Description: Inhalation twice daily of 160mg
Study NCT01394835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin
Description: Inhalation twice daily .Dosage 160mg
Study NCT01394835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAT
Description: Inhalation twice daily' 160mg
Study NCT02387385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling (Tecotherm)
Description: Whole body cooling to 33 to 34 C using Tecotherm
Study NCT00969007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification counselling
Description: Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
Study NCT02516085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02516085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Study NCT01892007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed RM - Online adaptive working memory training
Study NCT03463395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reza band
Description: Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
Study NCT01892007 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cogmed RM - Online non-adaptive (placebo) working memory training
Study NCT04153357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
Study NCT04153357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: c-mac
Description: device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv on day 1 of each 3 week cycle until disease progression
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg 1v on day 1 of each 3 week cycle until disease progression
Study NCT00806923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
Study NCT00131456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 375mg/day
Study NCT00131456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03637712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Algorithm
Description: This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily for 6 months
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily for 6 months
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 mg/2 mg/3 mg once daily
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: 1 mg/2 mg/3 mg once daily
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: >=1000 mg twice daily
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: >=1000 mg twice daily
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: TDD > 10 IU once/twice daily
Study NCT01341717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: TDD > 10 IU once/twice daily
Study NCT02263911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir (also known as GSK1349572) 50 mg taken once daily
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla once daily on an empty stomach
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: taken once daily; also known as EPZICOM
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir/Lamivudine Placebo
Description: matching placebo taken once daily
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir placebo
Description: matching placebo taken once daily
Study NCT01263015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla placebo
Description: matching placebo taken once daily on an empty stomach
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dezocine injection
Description: Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjusted Dezocine injection
Description: Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dynastat or Flurbiprofen Axetil jinjection
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjusted Dynastat or Flurbiprofen Axetil jinjection
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
Study NCT03823846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative rehabilitation
Description: Rehabilitation was conducted at 8:00am and 2:00pm.
Study NCT03823846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative rehabilitation
Description: Rehabilitation was conducted at 8:00am and 2:00pm.
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal analgesia pump administration
Description: Dose of analgesia pump was added if needed.
Study NCT03823846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjusted analgesia pump administration
Description: Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
Study NCT06546072 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT01345565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human hepatocytes
Description: The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant.
Study NCT02127294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter patent foreman ovale closure
Study NCT04459975 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis
Study NCT00203021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
Study NCT03353766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early crossbite correction with Q-H Device
Description: Crossbite treatment in deciduous dentition with Quad-Helix appliance
Study NCT01401699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI)
Description: Optical Frequency Domain (OFDI) imaging of esophagus
Study NCT00697294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tri-Vi-Sol
Description: All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
Study NCT02163213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
Study NCT02650128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Rx Lithoplasty® System
Description: The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
Study NCT02834104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMI
Study NCT02834104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myocardial biopsy
Study NCT02773771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxy-beta-methylbutyrate
Description: HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
Study NCT02773771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
Study NCT02773771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vital HP®
Description: Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
Study NCT02773771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vital HP®
Description: Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
Study NCT01057056 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: mind-body intervention
Description: multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
Study NCT01012752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: modified allergen extract
Description: subcutaneous injections
Study NCT01012752 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study NCT02048410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei B21060
Description: combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
Study NCT02048410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low satured diet
Study NCT02048410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low satured diet
Study NCT01454349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
Study NCT01454349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of matching placebo
Study NCT04408768 — intervention group
Intervention type: OTHER
Intervention: standard protocol for stroke patients
Description: Standard protocol for stroke patients
Study NCT03106285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17938
Description: 5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
Study NCT03106285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of placebo drops
Study NCT00175409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
Study NCT00175409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
Study NCT04400084 — intervention group
Intervention type: OTHER
Intervention: Placenta perfusion
Description: Placenta perfusion in double closed circuit, during 3 hours
Study NCT00447473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
Study NCT00447473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
Study NCT00447473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone
Description: Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
Study NCT02194322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses
Study NCT02194322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03227068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDSS - symptom management
Description: All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
Study NCT03227068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDSS - support for the caregiver
Description: All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
Study NCT02406443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaglitpin
Description: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
Study NCT02406443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (no medicinal ingredients) administered once daily for 28 days
Study NCT03737331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fractal visual cueing
Description: Walking to an external visual fractal (i.e., pink noise) stimulus.
Study NCT03737331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Periodic visual cueing
Description: Walking to an external visual periodic (i.e., invariant) stimulus.
Study NCT03737331 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Random visual cueing
Description: Walking to an external visual random (i.e., white noise) stimulus.